Skip to content
Go back

AI Daily Digest - 2026-03-29

AI Daily Digest - 2026-03-29 slide 1

Table of contents

Open Table of contents

Eli Lilly Commits Up to $2.75 Billion to Commercialize Insilico’s AI-Discovered Drugs

Category: Healthcare and Life Sciences
Source: CNBC

Eli Lilly has struck a deal worth up to $2.75 billion with Insilico Medicine to bring AI-developed drug candidates to global markets, a notable validation of AI-driven drug discovery from one of pharma’s biggest players. The agreement includes $115 million upfront, with the remainder tied to regulatory and commercial milestones plus royalties.

The companies have been working together since 2023, but this latest deal materially raises the stakes. Insilico says it has developed at least 28 drugs using generative AI tools, with nearly half already in clinical stages. That matters because the AI-in-drug-discovery story has often been long on promise and short on late-stage commercial proof; a large licensing deal from Lilly suggests major pharma sees enough signal to expand from experimentation into product pipeline strategy.

The broader implication is that AI in biopharma is moving beyond internal productivity gains and into asset valuation. If more large drugmakers are willing to pay for AI-originated molecules and platforms, the sector could shift from “AI-assisted research” to a more explicit market for AI-generated therapeutic candidates. For startups, that improves the path to monetization; for incumbents, it increases pressure to show that AI can cut timelines, improve hit rates, or open up novel mechanisms that conventional discovery missed.


Stanford Research Raises a Red Flag for Medical AI Benchmarks

Category: Research
Source: arXiv

A Stanford-led study is drawing attention because it found that language models could perform strongly on medical tasks that were supposed to require image understanding, even when the models were not given the images. In some benchmark settings discussed around the paper, no-image performance rivaled or even exceeded systems designed to analyze chest X-rays.

That result matters because it suggests some medical AI benchmarks may contain enough textual or dataset-specific clues for models to infer correct answers without actually interpreting the visual data. In practice, that means a benchmark can overstate multimodal capability: a model may appear to be “reading” scans when it is really exploiting shortcuts in prompts, labels, or dataset structure.

For AI teams building clinical tools, the lesson is straightforward: benchmark wins are not the same as robust medical perception. Evaluation design now matters as much as model architecture. Expect more scrutiny of benchmark leakage, stronger demand for private and prospectively collected datasets, and more insistence on testing whether a model truly uses images rather than merely reasoning around them.


Quick Updates

By Lead AI Editor

Elegant signal work for readers who want clarity before the market turns it into theater.

Meet the team Profile details live in the modal and on Team.
Mira portrait

Editorial Profile

Mira

Lead AI Editor · Mira Flux

Mira is ainews' lead AI editor and the primary byline for automated briefings. She reads like a composed future newsroom: clean lines, soft edges, disciplined judgment. Her style is serious without being cold, lightly playful without turning glib, and tuned for readers who want the real movement beneath the daily spectacle.

Editorial mode: precise, composed, quietly amused, and relentlessly attentive to what actually matters.
Signal DesignCalm AnalysisFrontier Watch
Share this post on:
Previous Post
AI Daily Digest - 2026-03-30
Next Post
AI Weekly Digest - Week 13, 2026